Clinical Research Directory

Inclusion Criteria: * Male or non-pregnant, non-nursing female ≥18 years of age at screening * Patients with a diagnosis of RA who fulfil the 2010 ACR/EULAR diagnostic criteria24 (see Appendix 5, 10.4) * Medical treatment with cs/ts/bDMARDs (incl. prednisolone) considered stable by the healthcare provider the last 6 months * Low disease activity or remission (CDAI\<10 / DAS28\<3.2) at inclusion * \<2 swollen joints * Not deemed inappropriate for remote monitoring by the healthcare provider * Capable of understanding and signing an informed consent form * Access to a smartphone or tablet * Able to speak and understand Norwegian language Exclusion Criteria: Medical conditions: * Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis. * Indications of active tuberculosis (TB) * Treated with intravenous DMARD (e.g., rituximab and infliximab) Diagnostic assessments: * Abnormal renal function, defined as serum creatinine \>142 µmol/L in female and \>168 µmol/L in male, or glomerular filtration rate (GFR) \<40 mL/min/1.73 m2 * Abnormal liver function (defined as Aspartate Transaminate (AST)/Alanine Transaminase (ALT) \>3 x upper normal limit), active or recent hepatitis * Leukopenia and/or thrombocytopenia Other: * Pregnancy and/or breastfeeding (current at screening or planned within the duration of the study) * Severe psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible. * Deemed unsuitable for remote monitoring by medical doctor